Table 1 Liver biochemistry tests during follow up
From: Hepatobiliary scintigraphy may improve radioembolization treatment planning in HCC patients
Case | Time to RE (days) | Bilirubin (mg/dL) | Albumin (g/L) | AST (U/L) | ALT (U/L) | ALP (U/L) | INR | Ascites | AFP (μg/L) |
|---|---|---|---|---|---|---|---|---|---|
1 | −1 | 0.9 | 31 | 72 | 60 | 252 | 1.24a | no | 750 |
+12 | 1.2 | 30 | 75 | 51 | 326 | – | minimal | – | |
+35 | 1.1 | 27 | 107 | 59 | 290 | 3.49a | – | – | |
+65 | 1.1 | 24 | 60 | 47 | 286 | 5.79a | diffuse | – | |
+86 | 2.4 | 20 | 62 | 36 | 347 | 1.36a | – | – | |
2 | −1 | 1.9 | 27 | 76 | 60 | 115 | 1.38 | minimal | 140 |
+14 | 4.3 | 25 | 96 | 58 | 138 | – | moderate | – | |
+18 | 6.7 | 22 | 72 | 84 | 67 | 1.8 | diffuse | – | |
+33 | 5.6 | 25 | 69 | 45 | 100 | 0.9 | diffuse | – | |
+61 | 8.2 | 23 | 69 | 170 | 126 | 1.7 | massive | – | |
+95 | 11.1 | 23 | 250 | 212 | 153 | – | massive | 36 | |
3 | 0 | 1.6 | 25 | 61 | 46 | 122 | 1.18 | minimal | 270 |
+14 | 2.5 | 28 | 80 | 50 | 143 | 1.16 | moderate | 210 | |
+30 | 2.3 | 22 | 58 | 32 | 126 | 1.20 | moderate | – | |
+71 | 2.2 | 23 | 63 | 37 | 144 | 1.20 | moderate | – | |
+160 | 2.9 | 23 | 67 | 32 | 156 | 1.20 | massive | 5200 |